Skip to main content
Top

19-11-2023 | Pancreatic Cancer | Pancreatic Tumors

ASO Practice Guidelines Series: Management of Resectable, Borderline Resectable, and Locally Advanced Pancreas Cancer

Authors: Kevin M. Turner, MD, Gregory C. Wilson, MD, Sameer H. Patel, MD, Syed A. Ahmad, MD

Published in: Annals of Surgical Oncology

Login to get access

Abstract

Pancreatic adenocarcinoma is an aggressive disease marked by high rates of both local and distant failure. In the minority of patients with potentially resectable disease, multimodal treatment paradigms have allowed for prolonged survival in an increasingly larger pool of well-selected patients. Therefore, it is critical for surgical oncologists to be abreast of current guideline recommendations for both surgical management and multimodal therapy for pancreas cancer. We discuss these guidelines, as well as the underlying data supporting these positions, to offer surgical oncologists a framework for managing patients with pancreatic adenocarcinoma.
Literature
2.
go back to reference Society AC. Cancer facts and figures 2021. Atlanta: American Cancer Society; 2021. Society AC. Cancer facts and figures 2021. Atlanta: American Cancer Society; 2021.
3.
go back to reference Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4(6):437–50. PubMedCrossRef Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4(6):437–50. PubMedCrossRef
4.
go back to reference Makohon-Moore AP, Matsukuma K, Zhang M, et al. Precancerous neoplastic cells can move through the pancreatic ductal system. Nature. 2018;561(7722):201–5. PubMedPubMedCentralCrossRef Makohon-Moore AP, Matsukuma K, Zhang M, et al. Precancerous neoplastic cells can move through the pancreatic ductal system. Nature. 2018;561(7722):201–5. PubMedPubMedCentralCrossRef
5.
go back to reference Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3(92):92–66. CrossRef Wu J, Matthaei H, Maitra A, et al. Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med. 2011;3(92):92–66. CrossRef
6.
go back to reference Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022;163(2):386–402. PubMedCrossRef Wood LD, Canto MI, Jaffee EM, Simeone DM. Pancreatic cancer: pathogenesis, screening, diagnosis, and treatment. Gastroenterology. 2022;163(2):386–402. PubMedCrossRef
8.
go back to reference Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81. PubMedCrossRef Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81. PubMedCrossRef
10.
go back to reference Gemenetzis G, Groot VP, Yu J, et al. Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status: Results of the prospective CLUSTER study. Ann Surg. 2018;268(3):408–20. PubMedCrossRef Gemenetzis G, Groot VP, Yu J, et al. Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status: Results of the prospective CLUSTER study. Ann Surg. 2018;268(3):408–20. PubMedCrossRef
11.
go back to reference Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406. PubMedCrossRef Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406. PubMedCrossRef
13.
go back to reference National Comprehensive Cancer Network. Pancreatic cancer (Version 2.2023). Accessed 20 Aug 2023. National Comprehensive Cancer Network. Pancreatic cancer (Version 2.2023). Accessed 20 Aug 2023.
14.
go back to reference Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339–47. PubMedCrossRef Canto MI, Harinck F, Hruban RH, et al. International Cancer of the Pancreas Screening (CAPS) consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339–47. PubMedCrossRef
15.
go back to reference National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic (Version 3.2023). Accessed 22 Aug 2023. National Comprehensive Cancer Network. Genetic/familial high-risk assessment: breast, ovarian, and pancreatic (Version 3.2023). Accessed 22 Aug 2023.
16.
go back to reference Shindo K, Yu J, Suenaga M, et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol. 2017;35(30):3382–90. PubMedPubMedCentralCrossRef Shindo K, Yu J, Suenaga M, et al. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol. 2017;35(30):3382–90. PubMedPubMedCentralCrossRef
17.
18.
go back to reference Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the American pancreatic association. Gastroenterology. 2014;146(1):291–304. PubMedCrossRef Al-Hawary MM, Francis IR, Chari ST, et al. Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the society of abdominal radiology and the American pancreatic association. Gastroenterology. 2014;146(1):291–304. PubMedCrossRef
19.
go back to reference Vachiranubhap B, Kim YH, Balci NC, Semelka RC. Magnetic resonance imaging of adenocarcinoma of the pancreas. Top Magn Reson Imaging. 2009;20(1):3–9. PubMedCrossRef Vachiranubhap B, Kim YH, Balci NC, Semelka RC. Magnetic resonance imaging of adenocarcinoma of the pancreas. Top Magn Reson Imaging. 2009;20(1):3–9. PubMedCrossRef
20.
go back to reference Motosugi U, Ichikawa T, Morisaka H, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology. 2011;260(2):446–53. PubMedCrossRef Motosugi U, Ichikawa T, Morisaka H, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology. 2011;260(2):446–53. PubMedCrossRef
21.
go back to reference Expert Panel on Gastrointestinal I, Qayyum A, Tamm EP, et al. ACR Appropriateness Criteria ® staging of pancreatic ductal adenocarcinoma. J Am Coll Radiol. 2017;14(11S):S560-9. Expert Panel on Gastrointestinal I, Qayyum A, Tamm EP, et al. ACR Appropriateness Criteria ® staging of pancreatic ductal adenocarcinoma. J Am Coll Radiol. 2017;14(11S):S560-9.
22.
go back to reference Steinberg W. The clinical utility of the CA 19–9 tumor-associated antigen. Am J Gastroenterol. 1990;85(4):350–5. PubMed Steinberg W. The clinical utility of the CA 19–9 tumor-associated antigen. Am J Gastroenterol. 1990;85(4):350–5. PubMed
23.
go back to reference Ong SL, Sachdeva A, Garcea G, et al. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci. 2008;53(12):3213–7. PubMedCrossRef Ong SL, Sachdeva A, Garcea G, et al. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci. 2008;53(12):3213–7. PubMedCrossRef
24.
go back to reference Committee ASoP, Eloubeidi MA, Decker GA, et al. The role of endoscopy in the evaluation and management of patients with solid pancreatic neoplasia. Gastrointest Endosc. 2016;83(1):17–28. CrossRef Committee ASoP, Eloubeidi MA, Decker GA, et al. The role of endoscopy in the evaluation and management of patients with solid pancreatic neoplasia. Gastrointest Endosc. 2016;83(1):17–28. CrossRef
25.
go back to reference Deerenberg EB, Poley JW, Hermans JJ, Ganesh S, van der Harst E, van Eijck CH. Role of endoscopic ultrasonography in patients suspected of pancreatic cancer with negative helical MDCT scan. Dig Surg. 2011;28(5–6):398–403. PubMedCrossRef Deerenberg EB, Poley JW, Hermans JJ, Ganesh S, van der Harst E, van Eijck CH. Role of endoscopic ultrasonography in patients suspected of pancreatic cancer with negative helical MDCT scan. Dig Surg. 2011;28(5–6):398–403. PubMedCrossRef
26.
go back to reference Nawaz H, Fan CY, Kloke J, et al. Performance characteristics of endoscopic ultrasound in the staging of pancreatic cancer: a meta-analysis. JOP. 2013;14(5):484–97. PubMed Nawaz H, Fan CY, Kloke J, et al. Performance characteristics of endoscopic ultrasound in the staging of pancreatic cancer: a meta-analysis. JOP. 2013;14(5):484–97. PubMed
27.
go back to reference Levine I, Trindade AJ. Endoscopic ultrasound fine needle aspiration vs fine needle biopsy for pancreatic masses, subepithelial lesions, and lymph nodes. World J Gastroenterol. 2021;27(26):4194–207. PubMedPubMedCentralCrossRef Levine I, Trindade AJ. Endoscopic ultrasound fine needle aspiration vs fine needle biopsy for pancreatic masses, subepithelial lesions, and lymph nodes. World J Gastroenterol. 2021;27(26):4194–207. PubMedPubMedCentralCrossRef
28.
go back to reference Micames C, Jowell PS, White R, et al. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc. 2003;58(5):690–5. PubMedCrossRef Micames C, Jowell PS, White R, et al. Lower frequency of peritoneal carcinomatosis in patients with pancreatic cancer diagnosed by EUS-guided FNA vs. percutaneous FNA. Gastrointest Endosc. 2003;58(5):690–5. PubMedCrossRef
29.
go back to reference Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet. 1992;340(8834–8835):1488–92. PubMedCrossRef Davids PH, Groen AK, Rauws EA, Tytgat GN, Huibregtse K. Randomised trial of self-expanding metal stents versus polyethylene stents for distal malignant biliary obstruction. Lancet. 1992;340(8834–8835):1488–92. PubMedCrossRef
30.
go back to reference van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010;362(2):129–37. PubMedCrossRef van der Gaag NA, Rauws EA, van Eijck CH, et al. Preoperative biliary drainage for cancer of the head of the pancreas. N Engl J Med. 2010;362(2):129–37. PubMedCrossRef
31.
go back to reference De Bellis M, Sherman S, Fogel EL, et al. Tissue sampling at ERCP in suspected malignant biliary strictures (Part 1). Gastrointest Endosc. 2002;56(4):552–61. PubMedCrossRef De Bellis M, Sherman S, Fogel EL, et al. Tissue sampling at ERCP in suspected malignant biliary strictures (Part 1). Gastrointest Endosc. 2002;56(4):552–61. PubMedCrossRef
32.
go back to reference Nakao A, Kanzaki A, Fujii T, et al. Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer. Ann Surg. 2012;255(1):103–8. PubMedCrossRef Nakao A, Kanzaki A, Fujii T, et al. Correlation between radiographic classification and pathological grade of portal vein wall invasion in pancreatic head cancer. Ann Surg. 2012;255(1):103–8. PubMedCrossRef
33.
go back to reference Ghaneh P, Kleeff J, Halloran CM, et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg. 2019;269(3):520–9. PubMedCrossRef Ghaneh P, Kleeff J, Halloran CM, et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann Surg. 2019;269(3):520–9. PubMedCrossRef
34.
go back to reference Sohal DPS, Duong M, Ahmad SA, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):421–7. PubMedCrossRef Sohal DPS, Duong M, Ahmad SA, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):421–7. PubMedCrossRef
35.
go back to reference Chatzizacharias NA, Tsai S, Griffin M, et al. Locally advanced pancreas cancer: staging and goals of therapy. Surgery. 2018;163(5):1053–62. PubMedCrossRef Chatzizacharias NA, Tsai S, Griffin M, et al. Locally advanced pancreas cancer: staging and goals of therapy. Surgery. 2018;163(5):1053–62. PubMedCrossRef
36.
go back to reference Katz MH, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20(8):2787–95. PubMedPubMedCentralCrossRef Katz MH, Marsh R, Herman JM, et al. Borderline resectable pancreatic cancer: need for standardization and methods for optimal clinical trial design. Ann Surg Oncol. 2013;20(8):2787–95. PubMedPubMedCentralCrossRef
37.
go back to reference Bernard V, Kim DU, San Lucas FA, et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer. Gastroenterology. 2019;156(1):108–18. PubMedCrossRef Bernard V, Kim DU, San Lucas FA, et al. Circulating nucleic acids are associated with outcomes of patients with pancreatic cancer. Gastroenterology. 2019;156(1):108–18. PubMedCrossRef
38.
go back to reference Patel SH, Katz MHG, Ahmad SA. The landmark series: preoperative therapy for pancreatic cancer. Ann Surg Oncol. 2021;28(8):4104–29. PubMedCrossRef Patel SH, Katz MHG, Ahmad SA. The landmark series: preoperative therapy for pancreatic cancer. Ann Surg Oncol. 2021;28(8):4104–29. PubMedCrossRef
39.
go back to reference Khorana AA, McKernin SE, Berlin J, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. J Clin Oncol. 2019;37(23):2082–8. PubMedCrossRef Khorana AA, McKernin SE, Berlin J, et al. Potentially curable pancreatic adenocarcinoma: ASCO clinical practice guideline update. J Clin Oncol. 2019;37(23):2082–8. PubMedCrossRef
40.
go back to reference Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65. PubMedPubMedCentralCrossRef Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011;29(25):3457–65. PubMedPubMedCentralCrossRef
41.
go back to reference Dale W, Hemmerich J, Kamm A, et al. Geriatric assessment improves prediction of surgical outcomes in older adults undergoing pancreaticoduodenectomy: a prospective cohort study. Ann Surg. 2014;259(5):960–5. PubMedCrossRef Dale W, Hemmerich J, Kamm A, et al. Geriatric assessment improves prediction of surgical outcomes in older adults undergoing pancreaticoduodenectomy: a prospective cohort study. Ann Surg. 2014;259(5):960–5. PubMedCrossRef
42.
go back to reference Palta M, Godfrey D, Goodman KA, et al. Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2019;9(5):322–32. PubMedCrossRef Palta M, Godfrey D, Goodman KA, et al. Radiation therapy for pancreatic cancer: executive summary of an ASTRO clinical practice guideline. Pract Radiat Oncol. 2019;9(5):322–32. PubMedCrossRef
44.
go back to reference Pawlik TM, Laheru D, Hruban RH, et al. Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol. 2008;15(8):2081–8. PubMedPubMedCentralCrossRef Pawlik TM, Laheru D, Hruban RH, et al. Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol. 2008;15(8):2081–8. PubMedPubMedCentralCrossRef
45.
go back to reference Brauer DG, Strand MS, Sanford DE, et al. Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. HPB (Oxford). 2017;19(2):133–9. PubMedCrossRef Brauer DG, Strand MS, Sanford DE, et al. Utility of a multidisciplinary tumor board in the management of pancreatic and upper gastrointestinal diseases: an observational study. HPB (Oxford). 2017;19(2):133–9. PubMedCrossRef
46.
go back to reference Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128–37. PubMedCrossRef Birkmeyer JD, Siewers AE, Finlayson EV, et al. Hospital volume and surgical mortality in the United States. N Engl J Med. 2002;346(15):1128–37. PubMedCrossRef
47.
go back to reference Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110(6):1227–34. PubMedCrossRef Bilimoria KY, Bentrem DJ, Ko CY, et al. Multimodality therapy for pancreatic cancer in the U.S.: utilization, outcomes, and the effect of hospital volume. Cancer. 2007;110(6):1227–34. PubMedCrossRef
48.
go back to reference Hoos WA, James PM, Rahib L, Talley AW, Fleshman JM, Matrisian LM. Pancreatic cancer clinical trials and accrual in the United States. J Clin Oncol. 2013;31(27):3432–8. PubMedCrossRef Hoos WA, James PM, Rahib L, Talley AW, Fleshman JM, Matrisian LM. Pancreatic cancer clinical trials and accrual in the United States. J Clin Oncol. 2013;31(27):3432–8. PubMedCrossRef
49.
go back to reference Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81. PubMedCrossRef Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81. PubMedCrossRef
50.
go back to reference Nassour I, Parrish A, Baptist L, et al. National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. HPB (Oxford). 2023;2023:1323–8. CrossRef Nassour I, Parrish A, Baptist L, et al. National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. HPB (Oxford). 2023;2023:1323–8. CrossRef
51.
go back to reference Yeung RS, Weese JL, Hoffman JP, et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A phase II study. Cancer. 1993;72(7):2124–33. PubMedCrossRef Yeung RS, Weese JL, Hoffman JP, et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A phase II study. Cancer. 1993;72(7):2124–33. PubMedCrossRef
52.
go back to reference Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40(11):1220–30. PubMedCrossRef Versteijne E, van Dam JL, Suker M, et al. Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 2022;40(11):1220–30. PubMedCrossRef
53.
go back to reference Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215–22. PubMedCrossRef Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2/3 trial. Ann Surg. 2018;268(2):215–22. PubMedCrossRef
54.
go back to reference Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022;8(9):1263–70. PubMedPubMedCentralCrossRef Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022;8(9):1263–70. PubMedPubMedCentralCrossRef
55.
go back to reference Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without Erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844–53. PubMedCrossRef Hammel P, Huguet F, van Laethem JL, et al. Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without Erlotinib: the LAP07 randomized clinical trial. JAMA. 2016;315(17):1844–53. PubMedCrossRef
56.
go back to reference Katz MH, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg. 2016;151(8):e161137. PubMedPubMedCentralCrossRef Katz MH, Shi Q, Ahmad SA, et al. Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: alliance for clinical trials in oncology trial A021101. JAMA Surg. 2016;151(8):e161137. PubMedPubMedCentralCrossRef
57.
go back to reference Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–7. PubMedCrossRef Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12–7. PubMedCrossRef
58.
go back to reference Tzeng CW, Balachandran A, Ahmad M, et al. Serum carbohydrate antigen 19–9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014;16(5):430–8. PubMedCrossRef Tzeng CW, Balachandran A, Ahmad M, et al. Serum carbohydrate antigen 19–9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer. HPB (Oxford). 2014;16(5):430–8. PubMedCrossRef
59.
go back to reference Heger U, Sun H, Hinz U, et al. Induction chemotherapy in pancreatic cancer: CA 19–9 may predict resectability and survival. HPB (Oxford). 2020;22(2):224–32. PubMedCrossRef Heger U, Sun H, Hinz U, et al. Induction chemotherapy in pancreatic cancer: CA 19–9 may predict resectability and survival. HPB (Oxford). 2020;22(2):224–32. PubMedCrossRef
60.
go back to reference Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(21):2541–56. PubMedCrossRef Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2016;34(21):2541–56. PubMedCrossRef
61.
go back to reference Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32(6):504–12. PubMedCrossRef Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study. J Clin Oncol. 2014;32(6):504–12. PubMedCrossRef
62.
go back to reference Labori KJ, Bratlie SO, Biörserud C, et al. Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: a multicenter randomized phase-II trial (NORPACT-1). J Clin Oncol. 2023;41(17_suppl):LBA4005. CrossRef Labori KJ, Bratlie SO, Biörserud C, et al. Short-course neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer: a multicenter randomized phase-II trial (NORPACT-1). J Clin Oncol. 2023;41(17_suppl):LBA4005. CrossRef
63.
go back to reference Chawla A, Shi Q, Ko AH, et al. Alliance A021806: a phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer. J Clin Oncol. 2023;41(16_suppl):TPS4204. CrossRef Chawla A, Shi Q, Ko AH, et al. Alliance A021806: a phase III trial evaluating perioperative versus adjuvant therapy for resectable pancreatic cancer. J Clin Oncol. 2023;41(16_suppl):TPS4204. CrossRef
64.
go back to reference Janssen QP, van Dam JL, Bonsing BA, et al. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer. 2021;21(1):300. PubMedPubMedCentralCrossRef Janssen QP, van Dam JL, Bonsing BA, et al. Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2 trial): study protocol for a nationwide multicenter randomized controlled trial. BMC Cancer. 2021;21(1):300. PubMedPubMedCentralCrossRef
65.
go back to reference van Dam JL, Verkolf EMM, Dekker EN, et al. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. BMC Cancer. 2023;23(1):728. PubMedPubMedCentralCrossRef van Dam JL, Verkolf EMM, Dekker EN, et al. Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial. BMC Cancer. 2023;23(1):728. PubMedPubMedCentralCrossRef
66.
go back to reference Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(7):963–9. PubMedPubMedCentralCrossRef Murphy JE, Wo JY, Ryan DP, et al. Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial. JAMA Oncol. 2018;4(7):963–9. PubMedPubMedCentralCrossRef
67.
go back to reference Schwarz L, Bachet J-B, Meurisse A, et al. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy: a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). J Clin Oncol. 2022;40(16_suppl):4134. CrossRef Schwarz L, Bachet J-B, Meurisse A, et al. Resectable pancreatic adenocarcinoma neo-adjuvant FOLF(IRIN)OX-based chemotherapy: a multicenter, non-comparative, randomized, phase II trial (PANACHE01-PRODIGE48 study). J Clin Oncol. 2022;40(16_suppl):4134. CrossRef
68.
go back to reference Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–73. PubMedPubMedCentralCrossRef Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–73. PubMedPubMedCentralCrossRef
69.
go back to reference Koerkamp BG, Janssen QP, Dam JL, et al. Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial. Ann Oncol. 2023;34:S1254-335. Koerkamp BG, Janssen QP, Dam JL, et al. Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial. Ann Oncol. 2023;34:S1254-335.
70.
go back to reference Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):157–68. PubMedCrossRef Ghaneh P, Palmer D, Cicconi S, et al. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8(2):157–68. PubMedCrossRef
71.
go back to reference Hurt CN, Mukherjee S, Bridgewater J, et al. Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2015;93(4):810–8. PubMedPubMedCentralCrossRef Hurt CN, Mukherjee S, Bridgewater J, et al. Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2015;93(4):810–8. PubMedPubMedCentralCrossRef
72.
go back to reference Katz MHG, Shi Q, Meyers JP, et al. Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas. J Clin Oncol. 2021;39(3_suppl):377. CrossRef Katz MHG, Shi Q, Meyers JP, et al. Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas. J Clin Oncol. 2021;39(3_suppl):377. CrossRef
73.
go back to reference Ghaneh P, Palmer DH, Cicconi S, et al. ESPAC-5F: four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J Clin Oncol. 2020;38(15_suppl):4505. CrossRef Ghaneh P, Palmer DH, Cicconi S, et al. ESPAC-5F: four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J Clin Oncol. 2020;38(15_suppl):4505. CrossRef
74.
go back to reference Jones RP, Psarelli EE, Jackson R, et al. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial. JAMA Surg. 2019;154(11):1038–48. PubMedPubMedCentralCrossRef Jones RP, Psarelli EE, Jackson R, et al. Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: a secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial. JAMA Surg. 2019;154(11):1038–48. PubMedPubMedCentralCrossRef
75.
go back to reference Turner KM, Delman AM, Kharofa JR, et al. Radiation therapy in borderline resectable pancreatic cancer: a review. Surgery. 2022;172(1):284–90. PubMedCrossRef Turner KM, Delman AM, Kharofa JR, et al. Radiation therapy in borderline resectable pancreatic cancer: a review. Surgery. 2022;172(1):284–90. PubMedCrossRef
76.
go back to reference Fietkau R, Ghadimi M, Grützmann R, et al. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial. J Clin Oncol. 2022;40(16_suppl):4008. CrossRef Fietkau R, Ghadimi M, Grützmann R, et al. Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial. J Clin Oncol. 2022;40(16_suppl):4008. CrossRef
77.
go back to reference Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10. PubMedCrossRef Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350(12):1200–10. PubMedCrossRef
78.
go back to reference Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24. PubMedCrossRef Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011–24. PubMedCrossRef
79.
go back to reference Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406. PubMedCrossRef Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406. PubMedCrossRef
80.
go back to reference Tempero MA, Pelzer U, O’Reilly EM, et al. Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. J Clin Oncol. 2023;41(11):2007–19. PubMedCrossRef Tempero MA, Pelzer U, O’Reilly EM, et al. Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. J Clin Oncol. 2023;41(11):2007–19. PubMedCrossRef
81.
go back to reference Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899–903. PubMedCrossRef Kalser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985;120(8):899–903. PubMedCrossRef
82.
go back to reference Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82 ( discussion 782–4). PubMedPubMedCentralCrossRef Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg. 1999;230(6):776–82 ( discussion 782–4). PubMedPubMedCentralCrossRef
83.
go back to reference Smeenk HG, van Eijck CH, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg. 2007;246(5):734–40. PubMedCrossRef Smeenk HG, van Eijck CH, Hop WC, et al. Long-term survival and metastatic pattern of pancreatic and periampullary cancer after adjuvant chemoradiation or observation: long-term results of EORTC trial 40891. Ann Surg. 2007;246(5):734–40. PubMedCrossRef
84.
go back to reference Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81. PubMedCrossRef Neoptolemos JP, Stocken DD, Bassi C, et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010;304(10):1073–81. PubMedCrossRef
85.
go back to reference Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299(9):1019–26. PubMedCrossRef Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA. 2008;299(9):1019–26. PubMedCrossRef
86.
go back to reference Neoptolemos JP, Palmer DH, Ghaneh P, et al. ESPAC-4: a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: five-year follow-up. J Clin Oncol. 2020;38(15):4516. CrossRef Neoptolemos JP, Palmer DH, Ghaneh P, et al. ESPAC-4: a multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma: five-year follow-up. J Clin Oncol. 2020;38(15):4516. CrossRef
87.
go back to reference Conroy T, Castan F, Lopez A, et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol. 2022;8(11):1571–8. PubMedPubMedCentralCrossRef Conroy T, Castan F, Lopez A, et al. Five-year outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: a randomized clinical trial. JAMA Oncol. 2022;8(11):1571–8. PubMedPubMedCentralCrossRef
88.
go back to reference Beall MS, Dyer GA, Stephenson HE Jr. Disappointments in the management of patients with malignancy of pancreas, duodenum, and common bile duct. Arch Surg. 1970;101(4):461–5. PubMedCrossRef Beall MS, Dyer GA, Stephenson HE Jr. Disappointments in the management of patients with malignancy of pancreas, duodenum, and common bile duct. Arch Surg. 1970;101(4):461–5. PubMedCrossRef
89.
go back to reference Cameron JL, He J. Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg. 2015;220(4):530–6. PubMedCrossRef Cameron JL, He J. Two thousand consecutive pancreaticoduodenectomies. J Am Coll Surg. 2015;220(4):530–6. PubMedCrossRef
90.
go back to reference Altman AM, Wirth K, Marmor S, et al. Completion of adjuvant chemotherapy after upfront surgical resection for pancreatic cancer is uncommon yet associated with improved survival. Ann Surg Oncol. 2019;26(12):4108–16. PubMedCrossRef Altman AM, Wirth K, Marmor S, et al. Completion of adjuvant chemotherapy after upfront surgical resection for pancreatic cancer is uncommon yet associated with improved survival. Ann Surg Oncol. 2019;26(12):4108–16. PubMedCrossRef
92.
go back to reference Katz MH, Merchant NB, Brower S, et al. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol. 2011;18(2):337–44. PubMedCrossRef Katz MH, Merchant NB, Brower S, et al. Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial. Ann Surg Oncol. 2011;18(2):337–44. PubMedCrossRef
93.
go back to reference Nelson H, Hunt K, Veeramachaneni N, et al. Operative standards for cancer surgery. Alphen aan den Rijn: Wolter Kluwer; 2015. Nelson H, Hunt K, Veeramachaneni N, et al. Operative standards for cancer surgery. Alphen aan den Rijn: Wolter Kluwer; 2015.
94.
go back to reference Gudmundsdottir H, Yonkus JA, Alva-Ruiz R, et al. Yield of staging laparoscopy for pancreatic cancer in the modern era: analysis of more than 1,000 consecutive patients. J Am Coll Surg. 2023;237(1):49–57. PubMedPubMedCentralCrossRef Gudmundsdottir H, Yonkus JA, Alva-Ruiz R, et al. Yield of staging laparoscopy for pancreatic cancer in the modern era: analysis of more than 1,000 consecutive patients. J Am Coll Surg. 2023;237(1):49–57. PubMedPubMedCentralCrossRef
95.
go back to reference van Dongen JC, Versteijne E, Bonsing BA, et al. The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial. Eur J Surg Oncol. 2023;49(4):811–7. PubMedCrossRef van Dongen JC, Versteijne E, Bonsing BA, et al. The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial. Eur J Surg Oncol. 2023;49(4):811–7. PubMedCrossRef
96.
go back to reference Kooby DA, Lad NL, Squires MH 3rd, et al. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Ann Surg. 2014;260(3):494–501 ( discussion 501–3). PubMedCrossRef Kooby DA, Lad NL, Squires MH 3rd, et al. Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patients. Ann Surg. 2014;260(3):494–501 ( discussion 501–3). PubMedCrossRef
97.
go back to reference Baque P, Iannelli A, Delotte J, de Peretti F, Bourgeon A. Division of the right posterior attachments of the head of the pancreas with a linear stapler during pancreaticoduodenectomy: vascular and oncological considerations based on an anatomical cadaver-based study. Surg Radiol Anat. 2009;31(1):13–7. PubMedCrossRef Baque P, Iannelli A, Delotte J, de Peretti F, Bourgeon A. Division of the right posterior attachments of the head of the pancreas with a linear stapler during pancreaticoduodenectomy: vascular and oncological considerations based on an anatomical cadaver-based study. Surg Radiol Anat. 2009;31(1):13–7. PubMedCrossRef
98.
go back to reference Strasberg SM, Linehan DC, Hawkins WG. Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins. J Am Coll Surg. 2007;204(2):244–9. PubMedCrossRef Strasberg SM, Linehan DC, Hawkins WG. Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins. J Am Coll Surg. 2007;204(2):244–9. PubMedCrossRef
99.
go back to reference Shoup M, Conlon KC, Klimstra D, Brennan MF. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified? J Gastrointest Surg. 2003;7(8):946–52 ( discussion 952). PubMedCrossRef Shoup M, Conlon KC, Klimstra D, Brennan MF. Is extended resection for adenocarcinoma of the body or tail of the pancreas justified? J Gastrointest Surg. 2003;7(8):946–52 ( discussion 952). PubMedCrossRef
100.
go back to reference Tol JA, Gouma DJ, Bassi C, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2014;156(3):591–600. PubMedCrossRef Tol JA, Gouma DJ, Bassi C, et al. Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS). Surgery. 2014;156(3):591–600. PubMedCrossRef
101.
go back to reference Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 2002;236(3):355–66 ( discussion 366–8). PubMedPubMedCentralCrossRef Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality. Ann Surg. 2002;236(3):355–66 ( discussion 366–8). PubMedPubMedCentralCrossRef
102.
go back to reference Farnell MB, Pearson RK, Sarr MG, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery. 2005;138(4):618–28 ( discussion 628–30). PubMedCrossRef Farnell MB, Pearson RK, Sarr MG, et al. A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma. Surgery. 2005;138(4):618–28 ( discussion 628–30). PubMedCrossRef
103.
go back to reference Pawlik TM, Abdalla EK, Barnett CC, et al. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg. 2005;140(6):584–9 ( discussion 589–91). PubMedCrossRef Pawlik TM, Abdalla EK, Barnett CC, et al. Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg. 2005;140(6):584–9 ( discussion 589–91). PubMedCrossRef
104.
go back to reference Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg. 2012;36(4):884–91. PubMedCrossRef Zhou Y, Zhang Z, Liu Y, Li B, Xu D. Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg. 2012;36(4):884–91. PubMedCrossRef
105.
go back to reference Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8(8):935–49 ( discussion 949–50). PubMedCrossRef Tseng JF, Raut CP, Lee JE, et al. Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg. 2004;8(8):935–49 ( discussion 949–50). PubMedCrossRef
106.
go back to reference Katz MH, Fleming JB, Pisters PW, Lee JE, Evans DB. Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy. Ann Surg. 2008;248(6):1098–102. PubMedCrossRef Katz MH, Fleming JB, Pisters PW, Lee JE, Evans DB. Anatomy of the superior mesenteric vein with special reference to the surgical management of first-order branch involvement at pancreaticoduodenectomy. Ann Surg. 2008;248(6):1098–102. PubMedCrossRef
107.
go back to reference Ferreira N, Oussoultzoglou E, Fuchshuber P, et al. Splenic vein-inferior mesenteric vein anastomosis to lessen left-sided portal hypertension after pancreaticoduodenectomy with concomitant vascular resection. Arch Surg. 2011;146(12):1375–81. PubMedCrossRef Ferreira N, Oussoultzoglou E, Fuchshuber P, et al. Splenic vein-inferior mesenteric vein anastomosis to lessen left-sided portal hypertension after pancreaticoduodenectomy with concomitant vascular resection. Arch Surg. 2011;146(12):1375–81. PubMedCrossRef
108.
go back to reference Asbun HJ, Moekotte AL, Vissers FL, et al. The Miami International evidence-based guidelines on minimally invasive pancreas resection. Ann Surg. 2020;271(1):1–14. PubMedCrossRef Asbun HJ, Moekotte AL, Vissers FL, et al. The Miami International evidence-based guidelines on minimally invasive pancreas resection. Ann Surg. 2020;271(1):1–14. PubMedCrossRef
109.
go back to reference Hirono S, Kawai M, Okada K, et al. Pancreatic neck cancer has specific and oncologic characteristics regarding portal vein invasion and lymph node metastasis. Surgery. 2016;159(2):426–40. PubMedCrossRef Hirono S, Kawai M, Okada K, et al. Pancreatic neck cancer has specific and oncologic characteristics regarding portal vein invasion and lymph node metastasis. Surgery. 2016;159(2):426–40. PubMedCrossRef
110.
go back to reference Peters NA, Javed AA, Cameron JL, et al. Modified appleby procedure for pancreatic adenocarcinoma: Does improved neoadjuvant therapy warrant such an aggressive approach? Ann Surg Oncol. 2016;23(11):3757–64. PubMedCrossRef Peters NA, Javed AA, Cameron JL, et al. Modified appleby procedure for pancreatic adenocarcinoma: Does improved neoadjuvant therapy warrant such an aggressive approach? Ann Surg Oncol. 2016;23(11):3757–64. PubMedCrossRef
111.
go back to reference Datta J, Wilson GC, D’Angelica MI, et al. A call for caution in overinterpreting exceptional outcomes after radical surgery for pancreatic cancer: let the data speak. Ann Surg. 2021;274(1):e82-4. PubMedCrossRef Datta J, Wilson GC, D’Angelica MI, et al. A call for caution in overinterpreting exceptional outcomes after radical surgery for pancreatic cancer: let the data speak. Ann Surg. 2021;274(1):e82-4. PubMedCrossRef
112.
go back to reference Tee MC, Krajewski AC, Groeschl RT, et al. Indications and perioperative outcomes for pancreatectomy with arterial resection. J Am Coll Surg. 2018;227(2):255–69. PubMedCrossRef Tee MC, Krajewski AC, Groeschl RT, et al. Indications and perioperative outcomes for pancreatectomy with arterial resection. J Am Coll Surg. 2018;227(2):255–69. PubMedCrossRef
113.
go back to reference Burgart LJ, Chopp WV, Jain D. College of American Pathologists: protocol for the examination of specimens from patients with carcinoma of the Pancreas. 2021. Accessed 24 Aug 2023. Burgart LJ, Chopp WV, Jain D. College of American Pathologists: protocol for the examination of specimens from patients with carcinoma of the Pancreas. 2021. Accessed 24 Aug 2023.
114.
go back to reference Huebner M, Kendrick M, Reid-Lombardo KM, et al. Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16(5):920–6. PubMedCrossRef Huebner M, Kendrick M, Reid-Lombardo KM, et al. Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma. J Gastrointest Surg. 2012;16(5):920–6. PubMedCrossRef
115.
go back to reference Feinstein AR, Sosin DM, Wells CK. The Will rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312(25):1604–8. PubMedCrossRef Feinstein AR, Sosin DM, Wells CK. The Will rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med. 1985;312(25):1604–8. PubMedCrossRef
116.
go back to reference Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93(10):1232–7. PubMedCrossRef Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ, Anthoney A. Redefining the R1 resection in pancreatic cancer. Br J Surg. 2006;93(10):1232–7. PubMedCrossRef
117.
go back to reference Campbell F, Smith RA, Whelan P, et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology. 2009;55(3):277–83. PubMedCrossRef Campbell F, Smith RA, Whelan P, et al. Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin. Histopathology. 2009;55(3):277–83. PubMedCrossRef
118.
go back to reference Verbeke CS, Menon KV. Redefining resection margin status in pancreatic cancer. HPB (Oxford). 2009;11(4):282–9. PubMedCrossRef Verbeke CS, Menon KV. Redefining resection margin status in pancreatic cancer. HPB (Oxford). 2009;11(4):282–9. PubMedCrossRef
119.
go back to reference Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the know your tumor registry trial. Lancet Oncol. 2020;21(4):508–18. PubMedPubMedCentralCrossRef Pishvaian MJ, Blais EM, Brody JR, et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the know your tumor registry trial. Lancet Oncol. 2020;21(4):508–18. PubMedPubMedCentralCrossRef
120.
go back to reference Dreyer SB, Rae S, Bisset K, et al. The impact of molecular subtyping on pathological staging of pancreatic cancer. Ann Surg. 2023;277(2):e396-405. PubMedCrossRef Dreyer SB, Rae S, Bisset K, et al. The impact of molecular subtyping on pathological staging of pancreatic cancer. Ann Surg. 2023;277(2):e396-405. PubMedCrossRef
121.
go back to reference Kelly D, Jonker DJ, Ko Y-J, et al. GATA6 Expression as a predictor of response to perioperative chemotherapy in resectable pancreatic adenocarcinoma: a multicenter Canadian phase II study (NeoPancONE). J Clin Oncol. 2022;40(4_suppl):TPS638. CrossRef Kelly D, Jonker DJ, Ko Y-J, et al. GATA6 Expression as a predictor of response to perioperative chemotherapy in resectable pancreatic adenocarcinoma: a multicenter Canadian phase II study (NeoPancONE). J Clin Oncol. 2022;40(4_suppl):TPS638. CrossRef
122.
go back to reference Zhou Y, Song A, Wu L, Si X, Li Y. Second pancreatectomy for recurrent pancreatic ductal adenocarcinoma in the remnant pancreas: a pooled analysis. Pancreatology. 2016;16(6):1124–8. PubMedCrossRef Zhou Y, Song A, Wu L, Si X, Li Y. Second pancreatectomy for recurrent pancreatic ductal adenocarcinoma in the remnant pancreas: a pooled analysis. Pancreatology. 2016;16(6):1124–8. PubMedCrossRef
Metadata
Title
ASO Practice Guidelines Series: Management of Resectable, Borderline Resectable, and Locally Advanced Pancreas Cancer
Authors
Kevin M. Turner, MD
Gregory C. Wilson, MD
Sameer H. Patel, MD
Syed A. Ahmad, MD
Publication date
19-11-2023
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-023-14585-y